This kit is designed for the detection of binding activity between Human HLA-DRA and LAG3, using a homogeneous AlphaLISA assay (no wash step). This assay can facilitate the design and development of antibody therapeutics by using competitive binding to HLA-DRA and LAG3.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
|Part Number||Unit Size||List Price||Your Price||Quantity|
|AL3066C||500 Assay Points||1747.00 USD|
|AL3066F||5,000 Assay Points||14000.00 USD|
You successfully added item(s) to your cart
AlphaLISA technology allows detecting the binding of target proteins in a highly sensitive, quantitative, reproducible and user-friendly mode. In this AlphaLISA assay, a biotinylated LAG-3 binds to the Streptavidin-coated Alpha Donor beads, while His-tagged HLA DRA is captured by Anti-His AlphaLISA Acceptor beads. When LAG-3 binding to HLA DRA happens, Donor beads and Acceptor beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Human Leukocyte Antigen (HLA) is an MHC (major histocompatibility complex) class II cell surface receptor. HLA DRA is one of Antigen D related HLA class II (HLA DR) alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Lymphocyte activation gene-3 (LAG-3), also known as CD223, is a member of the immunoglobulin superfamily. LAG-3 binds to MHC class II with higher affinity, providing negative regulation of T cell receptor signaling. Binding of a homodimerized LAG-3/Ig fusion protein to MHC class II molecules induces maturation of immature dendritic cells and secretion of cytokines. Deletion of LAG-3 facilitates anti-cancer immune response, also blocks self-tolerance and increases susceptibility to autoimmune diseases. Because of its profound inhibitory role, blocking HLA DR and LAG-3 binding has been considered as promising therapeutic target for human autoimmune disease and cancers.
Disclaimer: For research use only. Not for use in diagnostic procedures.
|Assay Target||HLA-DRA, LAG3|
|Assay Target Class||Protein|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 Assay Points|
|Resource Type||File Name||File Format|
|Brochure||Alpha product listing||PDF 124 KB|
|Application Note||Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint||PDF 1 MB|
|Manual||Manual: AlphaLISA HLA-DRA/LAG-3 Binding Kit AL3066||PDF 494 KB|